Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-07-09
2008-12-30
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S257000, C514S267000, C544S239000
Reexamination Certificate
active
07470690
ABSTRACT:
Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.
REFERENCES:
patent: 4695568 (1987-09-01), Ninomiya et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4939136 (1990-07-01), Haeck et al.
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5434174 (1995-07-01), Gidda et al.
patent: 5438068 (1995-08-01), Eeckhout et al.
patent: 5470868 (1995-11-01), Young
patent: 5530008 (1996-06-01), Azcona et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5663343 (1997-09-01), van der Meij et al.
patent: 5708033 (1998-01-01), Kelley et al.
patent: 5945415 (1999-08-01), Kato et al.
patent: 5962494 (1999-10-01), Young
patent: 5977127 (1999-11-01), Bonnacker et al.
patent: 5977175 (1999-11-01), Lin
patent: 5985866 (1999-11-01), Müuller et al.
patent: 5990159 (1999-11-01), Meulemans et al.
patent: 6008227 (1999-12-01), Davies et al.
patent: 6054461 (2000-04-01), Fairbanks et al.
patent: 6117879 (2000-09-01), Fairbanks et al.
patent: 6156771 (2000-12-01), Rubin et al.
patent: 6194382 (2001-02-01), Crain et al.
patent: 6211171 (2001-04-01), Sawynok et al.
patent: 6235745 (2001-05-01), Megens
patent: 6284770 (2001-09-01), Mangel et al.
patent: 6300336 (2001-10-01), Eeckhout et al.
patent: 6303613 (2001-10-01), McInally et al.
patent: 6355647 (2002-03-01), Steiner et al.
patent: 6384042 (2002-05-01), Färber et al.
patent: 6429209 (2002-08-01), Mangel et al.
patent: 6440453 (2002-08-01), Fischer et al.
patent: 6441038 (2002-08-01), Loder et al.
patent: 6458795 (2002-10-01), Bergeron, Jr.
patent: 6465458 (2002-10-01), Wong et al.
patent: 6476078 (2002-11-01), Jerussi et al.
patent: 6558708 (2003-05-01), Lin
patent: 6566369 (2003-05-01), Cautreels et al.
patent: 6593336 (2003-07-01), Mangel et al.
patent: 7094786 (2006-08-01), Landau
patent: 7220748 (2007-05-01), Cavalla et al.
patent: 2001/0020025 (2001-09-01), Megens
patent: 2001/0044450 (2001-11-01), Mangel et al.
patent: 2001/0056110 (2001-12-01), Faerber et al.
patent: 2002/0002197 (2002-01-01), Mueller et al.
patent: 2002/0039599 (2002-04-01), Lin et al.
patent: 2002/0040033 (2002-04-01), Cautreels et al.
patent: 2002/0086880 (2002-07-01), Rubin et al.
patent: 2002/0086881 (2002-07-01), Rubin et al.
patent: 2002/0107244 (2002-08-01), Howard, Jr.
patent: 2003/0036549 (2003-02-01), Mangel et al.
patent: 2003/0125349 (2003-07-01), Cautreels et al.
patent: 2003/0158221 (2003-08-01), Zhang et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2004/0048874 (2004-03-01), Bardsley
patent: 2004/0147509 (2004-07-01), Landau
patent: 2004/0147510 (2004-07-01), Landau
patent: 2004/0254168 (2004-12-01), Landau
patent: 2004/0254169 (2004-12-01), Landau
patent: 2004/0254170 (2004-12-01), Landau
patent: 2004/0254171 (2004-12-01), Landau et al.
patent: 2004/0254172 (2004-12-01), Landau et al.
patent: 2004/0259862 (2004-12-01), Landau
patent: 2005/0032780 (2005-02-01), Landau
patent: 2005/0192270 (2005-09-01), Landau
patent: 2005/0239792 (2005-10-01), Cavalla et al.
patent: 2006/0167005 (2006-07-01), Cavalla et al.
patent: 2006/0217391 (2006-09-01), Landau
patent: 2431074 (2002-06-01), None
patent: 100 63 223 (2002-06-01), None
patent: 0150469 (1988-06-01), None
patent: 0 297 651 (1993-11-01), None
patent: 1 230 921 (2002-08-01), None
patent: WO 88/04173 (1988-06-01), None
patent: WO 94/01095 (1994-01-01), None
patent: WO 96/11009 (1996-04-01), None
patent: WO 98/01157 (1998-01-01), None
patent: WO 98/08520 (1998-03-01), None
patent: WO 98/09623 (1998-03-01), None
patent: WO 98/50037 (1998-11-01), None
patent: WO 00/48581 (2000-08-01), None
patent: WO 00/48597 (2000-08-01), None
patent: WO 00/51583 (2000-09-01), None
patent: WO 00/51584 (2000-09-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 02/07713 (2002-01-01), None
patent: WO 02/083926 (2002-10-01), None
patent: WO 02/083926 (2002-10-01), None
patent: WO 02/094249 (2002-11-01), None
patent: WO 03/061657 (2003-07-01), None
patent: WO 03/063873 (2003-08-01), None
patent: WO 03/077897 (2003-09-01), None
patent: WO 2004/004734 (2004-01-01), None
patent: WO 2004/019948 (2004-03-01), None
patent: WO 2004/058353 (2004-07-01), None
patent: WO 2004/058353 (2004-07-01), None
patent: WO 2004/062623 (2004-07-01), None
patent: WO 2004/062624 (2004-07-01), None
patent: WO 2004/062624 (2004-07-01), None
Wu et al. (Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor With 5-HT3 Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats. 2000. Japan. Journal of Pharmacology.83.pp. 31-38).
Crowell M. D., “The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome,”American Journal of Managed Care, 2001, 7:S252-S260.
Eguchi J. et al., “The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor With 5-HT3 Receptor Antagonism,”Pharmacology, Biochemistry and Behavior, 2000, 68:677-683.
“How to Avoid a Health Insurance Claim Denial- and What to do When You Can't,” [Retrieved on Mar. 15, 2005]. Retrieved from the Internet <URL:http://info.insure.com/health/claimdenial.html>, pp. 1-4.
Irritable Bowel Syndrome at a Glance—Nosology, Epidemiology, and Pathophysiology (Monograph I), Dec. 2002 [Retrieved on Dec. 12, 2002]. Retrieved from the Internet <URL:http://fdhn.org/html/education/gi/ibs—nosology.htm>, pp. 1-2.
“Dynogen Pharmaceuticals, Inc. Enters Into Agreement With Mitsubishi Pharma For Irritable Bowel Syndrome Compound,” Dynogen Pharmaceuticals, Inc. Press Release, pp. 1-2 [online], (Dec. 22, 2003). Retrieved from the Internet <URL: www.dynogen.com>.
Angel, I., et al. “Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT3Receptor Antagonist and Antiemetic Properties,”Eur. J. Pharmacol., 232(2/3):139-145 (1993).
Béïque, J.C., et al., “Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters,”Eur. J. Pharmacol., 349(1):129-132 (1998).
Burns, M.J., “The Pharmacology and Toxicology of Reboxetine,”Int. J. Med. Toxicol. 3(4):26 1-7 (2000).
Bymaster, F.P., et al. “Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors,”Neuropsychopharmacology, 25(6):871-880 (2001).
Camilleri, M., “Serotonergic Drugs: Emerging Therapies for Irritable Bowel Syndrome,” In Irritable Bowel Syndrome a Clinician's Guide, M. Camilleri and R. C. Spiller, eds., Chapt. 19; pp. 1-10 (2002).
Camilleri, M., “Serotonergic Modulation of Visceral Sensation: Lower Gut,”Gut 51(Supp. 1):i81-i86 (2002).
Center for Drug Evaluation and Research Application No. 020623; Pharmacology Reviews; Jul. 5, 1996, pp. 1-40.
Database CIN Jan. 5, 2004, “Life Sciences in Brief,” [online], (retrieved online Jan. 31, 2006). Retrieved from: STN Database, Accession No. 33(3):1518T.
Database IMSDRUGNEWS, R&D Focus Drug News, “DDP 225 Dynogen, Mitsubishi Pharma Licensing Agreement,” [online], Jan. 12, 2004. Retrieved from: STN Database, Accession No. 2004:188.
Depoortere, I., et al., “Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis,”J. Pharmacol. Exp. Ther., 294(3): 983-990 (2000).
Drossman, D.A., et al., “Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development,”Gastroenterology, 112: 2120-2137 (1997).
Eguchi, J., et al., “Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride,”Arzneim.-Forsch./Drug Res., 47(12): 1337-1347 (1997).
Fairweather, D.B., et al., “The
Cavalla David
Gristwood Robert William
Dynogen Pharmaceuticals, Inc.
Hamilton Brook Smith & Reynolds P.C.
Padmanabhan Sreeni
Soroush Layla
LandOfFree
4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)py... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)py..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)py... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4041260